Eli Lilly and Company $LLY Shares Sold by StoneCrest Wealth Management Inc.

StoneCrest Wealth Management Inc. lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 16.1% in the second quarter, Holdings Channel.com reports. The institutional investor owned 5,351 shares of the company’s stock after selling 1,029 shares during the quarter. Eli Lilly and Company makes up 2.1% of StoneCrest Wealth Management Inc.’s portfolio, making the stock its 20th largest holding. StoneCrest Wealth Management Inc.’s holdings in Eli Lilly and Company were worth $6,418,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of LLY. Great Waters Wealth Management grew its holdings in shares of Eli Lilly and Company by 4.4% during the second quarter. Great Waters Wealth Management now owns 781 shares of the company’s stock valued at $937,000 after purchasing an additional 33 shares during the last quarter. Exchange Bank boosted its position in Eli Lilly and Company by 4.9% during the 2nd quarter. Exchange Bank now owns 1,091 shares of the company’s stock valued at $1,309,000 after purchasing an additional 51 shares during the period. HF Advisory Group LLC boosted its position in Eli Lilly and Company by 14.1% during the 2nd quarter. HF Advisory Group LLC now owns 2,246 shares of the company’s stock valued at $2,695,000 after purchasing an additional 278 shares during the period. Arista Wealth Management LLC grew its stake in Eli Lilly and Company by 1.0% during the 2nd quarter. Arista Wealth Management LLC now owns 5,856 shares of the company’s stock worth $7,024,000 after buying an additional 58 shares during the last quarter. Finally, Aletheian Wealth Advisors LLC increased its position in Eli Lilly and Company by 9.8% in the second quarter. Aletheian Wealth Advisors LLC now owns 1,021 shares of the company’s stock worth $1,225,000 after buying an additional 91 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Beat-and-raise quarter reinforces growth outlook. Lilly reported second-quarter revenue of approximately $22.97 billion and EPS of $8.38, exceeding consensus estimates. Revenue increased 47.7% year over year, and management raised 2026 revenue guidance to $85 billion-$87 billion from $82 billion-$85 billion, primarily because of strong demand for its diabetes and obesity medicines. Eli Lilly raises 2026 outlook again as Q2 soars past estimates
• Positive Sentiment: Weight-loss portfolio continues to drive investor enthusiasm. Mounjaro sales rose 91%, while Mounjaro and Zepbound together generated nearly $15 billion, widening Lilly’s lead over Novo Nordisk. Foundayo adoption is also gaining traction, Medicare access is expanding, and retatrutide is progressing toward a potential 2027 regulatory filing. LLY Q2 Earnings Call Raises Outlook as Foundayo Gains Traction
• Positive Sentiment: Analysts remain bullish. Truist raised its price target to $1,376 and maintained a Buy rating, while Cantor Fitzgerald lifted its target to $1,410 with an Overweight rating. Analysts cited durable incretin demand and the stronger long-term growth outlook. Eli Lilly’s Incretin Performance Supports Long-Term Growth
• Positive Sentiment: Favorable legal news removes a potential overhang. Lilly and Novo Nordisk defeated an antitrust lawsuit concerning the GLP-1 drug market, reducing near-term litigation risk. Lilly, Novo defeat antitrust lawsuit over GLP-1 drug market
• Neutral Sentiment: Retatrutide is being offered to some patients before FDA approval. Early access could generate real-world experience and strengthen demand, but the treatment remains subject to regulatory approval and related safety scrutiny. Eli Lilly offers new weight loss drug to some patients before FDA approval
• Negative Sentiment: Profit-taking and valuation concerns may be limiting the response. Following the earnings-driven advance, Lilly trades at roughly 40 times earnings and near its record high. Investors may be demanding continued execution, while expanding access through Amazon and competing obesity drugs could increase pricing and market-share pressure.

Wall Street Analysts Forecast Growth

LLY has been the subject of several analyst reports. Sanford C. Bernstein boosted their price target on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a report on Tuesday, July 14th. Bank of America boosted their price target on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Cantor Fitzgerald boosted their price objective on Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the stock an “overweight” rating in a research note on Thursday. Wall Street Zen lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 7th. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $1,292.18.

Eli Lilly and Company Trading Up 0.1%

Shares of LLY opened at $1,186.71 on Monday. The business’s 50-day moving average price is $1,159.38 and its 200 day moving average price is $1,047.62. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The stock has a market capitalization of $1.12 trillion, a P/E ratio of 39.82, a P/E/G ratio of 1.38 and a beta of 0.51. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. During the same period in the prior year, the firm earned $6.31 earnings per share. The business’s quarterly revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Analysts expect that Eli Lilly and Company will post 36.77 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 23.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.